SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Egetis Therapeutics Launches EMCITATE in the U.S.

Egetis Therapeutics announced the U.S. launch of EMCITATE for patients with MCT8 deficiency. The company says it is the first and only FDA-approved treatment for peripheral thyrotoxicosis in adults and pe

Related stories